Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
16 search results for:

Mantle cell lymphoma 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 10-04-2018 | Mantle cell lymphoma | News | Article

    Ibrutinib, venetoclax oral combination shows promise for mantle cell lymphoma

    Ibrutinib plus venetoclax could together be beneficial as oral treatment for mantle-cell lymphoma, suggests a phase II study published in The New England Journal of Medicine .

    Published in:
    N Engl J Med 2018; 378 : 1211–1223
  2. 19-12-2017 | Mantle cell lymphoma | News | Article

    Acalabrutinib monotherapy promising for relapsed, refractory mantle cell lymphoma

    Treatment with the second-generation Bruton tyrosine kinase inhibitor acalabrutinib induces durable responses in patients with relapsed or refractory mantle cell lymphoma, indicates the phase II ACE-LY-004 trial.

    Published in:
    Lancet 2017; Advance online publication, ASH 2017; Atlanta, Georgia, USA
  3. 06-11-2017 | FDA | News | Article
    approvalsWatch

    Acalabrutinib receives FDA go-ahead for mantle cell lymphoma

    medwireNews : The kinase inhibitor acalabrutinib has been approved by the US Food and Drug Administration for the treatment of adults with mantle cell lymphoma who have received at least one prior treatment.

  4. 10-10-2017 | Mantle cell lymphoma | News | Article
    Editor's pick

    Post-HSCT maintenance rituximab improves mantle-cell lymphoma survival

    Maintenance treatment with the anti-CD20 antibody rituximab after induction immunochemotherapy and autologous hematopoietic stem-cell transplantation is associated with a significant survival benefit among young patients with mantle-cell lymphoma, phase III trial findings show.

    Published in:
    N Engl J Med 2017; 377 : 1250–1260
  5. 02-02-2018 | Mantle cell lymphoma | Article

    Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study

    Rule S et al.  Leukemia  2018; doi:10.1038/s41375-018-0023-2

  6. 14-12-2021 | Tyrosine kinase inhibitors | Adis Journal Club | Article
    Targeted Oncology

    Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features

    BTK inhibitors have shown strong activity in a range of B-cell malignancies, including chronic lymphocytic leukaemia/small lymphocytic lymphoma, mantle cell lymphoma, Waldenström’s macroglobulinaemia and marginal zone lymphoma.

  7. 23-03-2017 | Lymphoma | News | Article

    Excessive toxicity halts idelalisib, lenalidomide plus rituximab lymphoma trials

    Two phase 1 trials investigating the safety and efficacy of combined idelalisib, lenalidomide, and rituximab in patients with relapsed and refractory follicular and mantle cell lymphoma have been stopped early due to excessive toxicity.

    Published in:
    Lancet Haematol 2017; Advance online publication
  8. 31-08-2017 | Lymphoma | Article

    Chimeric antigen receptor T-cell therapies for lymphoma

    ​​​​​​​ Nat Rev Clin Oncol  2017. doi:10.1038/nrclinonc.2017.128

    Author:
    Jennifer N. Brudno, James N. Kochenderfer
  9. 14-03-2017 | Lymphoma | Case report | Article

    SLL and CLL

    On the other hand, leukemic mantle cell lymphoma cells do not express CD23 even though they do co-express other B-cell surface antigens and CD5.

    Author:
    Tanya Siddiqi, Steven T Rosen
  10. 21-04-2017 | Lymphoma | Feature | Article

    Lymphoma in practice: Professor Anas Younes speaks to medwireNews

    Professor Anas Younes tells  medwireNews about the current issues in lymphoma practice, both for the clinician and patients.

  11. 01-08-2016 | Lymphoma | Article

    Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine

    An expert summary of the diagnostic and prognostic value of biomarkers related to alterations in the most common types of lymphoma at the genetic, epigenetic, protein, and tumor microenvironment levels. Mod Pathol  2016; 29: 1118–1142. doi:10.1038/modpathol.2016.92

    Author:
    Ruifang Sun, L Jeffrey Medeiros, Ken H Young
  12. 07-08-2017 | FDA | News | Article
    approvalsWatch

    First chronic GVHD therapy receives FDA support

    The small molecule therapy targeting Bruton’s tyrosine kinase has previously been approved for a number of hematologic conditions including chronic lymphocytic leukemia, small lymphocytic lymphoma with or without a 17p deletion, and mantle cell lymphoma.

  13. 29-12-2016 | Lymphoma | Article

    The landscape of new drugs in lymphoma

    In this review, Younes et al describe the most promising agents in clinical development for the treatment of lymphoma and provide expert opinion on new strategies that may streamline drug development. Nat Rev Clin Oncol  2017; 14: 335–346. doi:10.1038/nrclinonc.2016.205

    Author:
    Anas Younes, Stephen Ansell, Nathan Fowler, Wyndham Wilson, Sven de Vos, John Seymour, Ranjana Advani, Andres Forero, Frank Morschhauser, Marie Jose Kersten, Kensei Tobinai, Pier Luigi Zinzani, Emanuele Zucca, Jeremy Abramson, Julie Vose
  14. 16-09-2016 | Hematologic cancers | Book chapter | Article

    Risk factors, etiology, and pathogenesis

    In this chapter, the authors review current knowledge of the risk factors for and molecular  pathogenesis of the most common lymphomas. In:  Handbook of Lymphoma . Edited by Younes A. Springer International Publishing, 2016. doi:10.1007/978-3-319-08467-1_2

    Author:
    Anastasios Stathis, Colette Owens
  15. 28-09-2016 | Hematologic cancers | Book chapter | Article

    Staging

    In:  Handbook of Lymphoma . Edited by Younes A. Springer International Publishing, 2016. doi:10.1007/978-3-319-08467-1_4

    Author:
    Colette Owens, Anas Younes
  16. 03-11-2015 | Hematologic cancers | Article

    Novel immunotherapies in lymphoid malignancies

    An evaluation of the development of three distinct immunotherapy platforms for lymphoma treatment: chimeric antigen receptor T-cell therapy, bispecific T-cell engagers, and immune checkpoint inhibitors. Nat Rev Clin Oncol  2016; 13: 25–40. doi:10.1038/nrclinonc.2015.187

    Author:
    Connie Lee Batlevi, Eri Matsuki, Renier J. Brentjens, Anas Younes
  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.